Probiotic pill could tame COPD Flare-Ups, early trial hopes
NCT ID NCT07076290
First seen Feb 02, 2026 · Last updated Jun 19, 2026 · Updated 16 times
Summary
This early-stage trial tests an oral probiotic called R-3750 in 27 people with mild-to-moderate COPD. The main goal is to see if it is safe and tolerable. Researchers will also check if it improves breathing and quality of life using a standard questionnaire. The study is not yet recruiting.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COPD (CHRONIC OBSTRUCTIVE PULMONARY DISEASE) are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
R-3750 (a probiotic made from a modified bacterium, Lactococcus lactis)
What this could lead to
If it works, this could point toward a new way to manage COPD using a probiotic taken by mouth, potentially reducing flare-ups and improving breathing.
What could go wrong
This is a very early Phase 1 trial with only 27 people, focused on safety, not effectiveness. The probiotic may not show any benefit or could cause unexpected side effects.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.